Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Finished Goods (2020 - 2021)

UroGen Pharma (URGN) has disclosed Finished Goods for 2 consecutive years, with $888000.0 as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Finished Goods changed N/A year-over-year to $888000.0, compared with a TTM value of $888000.0 through Mar 2021, changed N/A, and an annual FY2020 reading of $913000.0, changed N/A over the prior year.
  • Finished Goods was $888000.0 for Q1 2021 at UroGen Pharma, down from $913000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $913000.0 in Q4 2020 and bottomed at $232000.0 in Q2 2020.